More on Sangamo Biosciences (SGMO): Q4 beats on both top and bottom line as higher revenues were...


More on Sangamo Biosciences (SGMO): Q4 beats on both top and bottom line as higher revenues were generated from the Company's collaboration agreements with Shire (SHPG), Dow AgroSciences (DAS) and Sigma-Aldrich Corporation (SIAL), plus additional research grants. The company guides FY2013 revenue slightly to the lower side of estimates, now expecting to earn between $20M -24M, versus the consensus of $23.09M. Shares -1% AH.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs